XMED:LSE:LSE-Xtrackers MSCI Europe UCITS ETF 1C (USD)

ETF | Others |

Last Closing

USD 93.45

Change

-0.95 (-1.01)%

Market Cap

N/A

Volume

1.20K

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-15 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XNID:LSE Xtrackers Nifty 50 Swap UCITS ..

-1.82 (-0.67%)

USD 292,109.69B
0R1O:LSE Amazon.com Inc.

-13.00 (-6.12%)

USD 1,607.29B
0R1I:LSE NVIDIA Corp.

-5.64 (-3.79%)

USD 618.20B
LCJP:LSE Lyxor Core MSCI Japan (DR) UCI..

-0.04 (-0.26%)

USD 584.80B
LCJD:LSE Amundi MSCI Japan (DR) UCITS E..

-0.14 (-0.81%)

USD 583.82B
0R1G:LSE Home Depot Inc.

N/A

USD 373.16B
0QZK:LSE Coca-Cola Co.

-1.05 (-1.67%)

USD 266.08B
0QZO:LSE 0QZO

+4.80 (+4.42%)

USD 258.54B
PRJU:LSE Amundi Index Solutions - Amund..

-0.25 (-0.85%)

USD 218.91B
0QZ3:LSE Qualcomm Inc.

-0.95 (-0.58%)

USD 202.26B

ETFs Containing XMED:LSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 2.43% 37% F 45% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 2.43% 38% F 44% F
Trailing 12 Months  
Capital Gain 9.65% 49% F 52% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 9.65% 50% F 51% F
Trailing 5 Years  
Capital Gain 34.66% 59% D- 64% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 34.66% 59% D- 65% D
Average Annual (5 Year Horizon)  
Capital Gain 11.46% 69% C- 71% C-
Dividend Return 11.46% 68% D+ 70% C-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 18.01% 40% F 56% F
Risk Adjusted Return 63.63% 69% C- 80% B-
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.